COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomod
Galimedix Therapeutics presents new preclinical data on GAL-201 at AD/PD 2025, showing promise in Alzheimer’s disease treatment by targeting misfolded Aβ monomers and reducing Aβ plaques with anti-inflammatory effects -
-
-
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator for oral Alzheimer's disease treatment at AD/PD(TM) 2025 Conference -
-
-
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation
